#HubbleClassic On January 19, 2015, Hubble captured a global map of Jupiter. This video was made from the observations.
Today, Jupiter is at opposition, meaning it shines in our sky all night long and is the closest to Earth that it’ll be all year.
#NASA #Hubble #classic #jupiter #planet #video #solarsystem #astronomy #space #science
Admin and Founder of The Secrets of the Universe and former intern at Indian Institute of Astrophysics, Bangalore, I am a science student pursuing Master’s in Physics from India. I love to study and write about Stellar Astrophysics, Relativity & Quantum Mechanics.
Mercury.
Great.
NASA is sending a small helicopter called Ingenuity with the Perseverance rover to Mars. It will be the first aircraft to fly in Mars if all goes well. [NASA has built a helicopter to explore Mars and it’s finally ready to launch](https://www.space.com/first-mars-helicopter-ready-to-launch.html)
Credit: NASA/JPL-Caltech
Moderna, Inc.’s COVID-19 vaccine candidate mRNA-1273 will advance to a 30,000-participant Phase III trial later this month, following publication of additional positive Phase I data from a study led by the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID).
Moderna said its closely-watched COVID-19 vaccine candidate mRNA-1273 will advance to a 30,000-participant Phase III trial later this month, following publication of additional positive Phase I data from a study led by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
The Phase III “COVE” study (NCT04470427) is expected to begin registration at study centers nationwide beginning on July 21 with study initiation set for six days later. The primary endpoint of the randomized, 1:1 placebo-controlled trial will be the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID-19 disease as defined by the need for hospitalization, and prevention of infection by SARS-CoV-2, Moderna said.
Moderna disclosed plans for the Phase III trial on Clinicaltrials.gov the same day that researchers from NIAID, Moderna, and their clinical research partners reported that mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2, in an interim analysis of results from their Phase I study (NCT04283461).
The first episode of “Hubble – Eye in the Sky” is here! 🎥
Have you ever wondered how a telescope in space is operated from down on Earth? Welcome to the Hubble control center. Find out how extraordinarily detailed observations are made with an orbiting space telescope, and get a look at Hubble’s on-the-ground replica that engineers and scientists use down here to fix problems up there.
For more on this video series, visit https://go.nasa.gov/3eveFO1.
Scientists from Trinity College Dublin have discovered a new link between impaired brain energy metabolism and delirium—a disorienting and distressing disorder particularly common in the elderly and one that is currently occurring in a large proportion of patients hospitalized with COVID-19 [15th of July 2020].
While much of the research was conducted in mice, additional work suggests overlapping mechanisms are at play in humans because cerebrospinal fluid (CSF) collected from patients suffering from delirium also contained tell-tale markers of altered brain glucose metabolism.
Collectively, the research, which has just been published in the Journal of Neuroscience, suggests that therapies focusing on brain energy metabolism may offer new routes to mitigating delirium.
No industry will be spared.
The pharmaceutical business is perhaps the only industry on the planet, where to get the product from idea to market the company needs to spend about a decade, several billion dollars, and there is about 90% chance of failure. It is very different from the IT business, where only the paranoid survive but a business where executives need to plan decades ahead and execute. So when the revolution in artificial intelligence fueled by credible advances in deep learning hit in 2013–2014, the pharmaceutical industry executives got interested but did not immediately jump on the bandwagon. Many pharmaceutical companies started investing heavily in internal data science R&D but without a coordinated strategy it looked more like re-branding exercise with the many heads of data science, digital, and AI in one organization and often in one department. And while some of the pharmaceutical companies invested in AI startups no sizable acquisitions were made to date. Most discussions with AI startups started with “show me a clinical asset in Phase III where you identified a target and generated a molecule using AI?” or “how are you different from a myriad of other AI startups?” often coming from the newly-minted heads of data science strategy who, in theory, need to know the market.
However, some of the pharmaceutical companies managed to demonstrate very impressive results in the individual segments of drug discovery and development. For example, around 2018 AstraZeneca started publishing in generative chemistry and by 2019 published several impressive papers that were noticed by the community. Several other pharmaceutical companies demonstrated impressive internal modules and Eli Lilly built an impressive AI-powered robotics lab in cooperation with a startup.
However, it was not possible to get a comprehensive overview and comparison of the major pharmaceutical companies that claimed to be doing AI research and utilizing big data in preclinical and clinical development until now. On June 15th, one article titled “The upside of being a digital pharma player” got accepted and quietly went online in a reputable peer-reviewed industry journal Drug Discovery Today. I got notified about the article by Google Scholar because it referenced several of our papers. I was about to discard the article as just another industry perspective but then I looked at the author list and saw a group of heavy-hitting academics, industry executives, and consultants: Alexander Schuhmacher from Reutlingen University, Alexander Gatto from Sony, Markus Hinder from Novartis, Michael Kuss from PricewaterhouseCoopers, and Oliver Gassmann from University of St. Gallen.
Scammers are everywhere now.
The defrauded bitcoin amassed during Wednesday’s monumental Twitter hack is already “on the move,” according to cryptocurrency tracing firm Chainalysis.
A star has been sent hurtling across the galaxy after undergoing a partial supernova, astronomers say.
A supernova is a powerful explosion that occurs when some stars reach the ends of their lives; in this case, the blast was not sufficient to destroy it.
Instead, it sent the star hurtling through space at 900,000 km/hr.
